Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)

Figures & data

Figure 1 Evolution of visual acuity in cohort over 8 years. (A) Yearly visual acuity and changes in ETDRS scores in comparison to baseline. (B) Mean change per year in ETRDS letter score in comparison to baseline, including standard error bars.

Abbreviations: n, eyes number; IQR, interquartile range; SD, standard deviation.

Table 1 Visual Outcomes At Year-8

A) Visual acuity in ETDRS letters change at Year 8
	n		%
Gain ≥ 15 letters	10		10.5
Gain 5–14 letters	20		21.1
Gain 0–4 letters	15		15.8
Loss 1–4 letters	4		4.2
Loss 5–14 letters	14		14.7
Loss ≥ 15 letters	32		33.7
B) Range of visual acuity levels achievements at Year-8 compared to baseline
Snellen Visual Acuity	Baseline VA		Year-8 VA
	n	%	n	%
VA 6/6–6/12	32	33.4	25	26.3
VA 6/6–6/18	49	51.6	39	41.1
VA 6/30–PL	24	25.3	38	40
VA 6/60 –PL	11	11.6	29	30.5

Abbreviations: VA, visual acuity; n, eyes number; PL, perception of light.

Table 2 Visual Acuity Comparisons Against Other Published Studies Over The Period Of Years 6 To 8

	Jacob et al^Citation10 (Belgium)	Our Results (NHS UK)	7-up Trial^Citation8 (USA)	Gillies et al^Citation9 (Australia)	Our Results (NHS UK)	Our Results (NHS UK)
Follow-up period (years)	6	6	7	7	7	8
Number of patients	88	95	65	131	95	95
Baseline average VA in ETDRS letters score	57.4 (12.7)	61.1 [46–70]	52.6, 53.2, 54.3	55.1 (18.8)	61.1 [46–70]	61.1 [46–70]
VA gain ≥15 letters	23%	17%	12%	16%	14%	11%
VA gain ≥ 0 letters	53%	60%	43%	–	56%	47%
VA loss ≥15 letters	21%	27%	34%	28%	30%	34%

Notes: For parametric data, it is presented as mean (standard deviation) and for non-parametric data, it is presented as median [interquartile range].

Abbreviation: VA, visual acuity.

Table 3 Comparison In Yearly Anti-VEGF Injections Frequency Against Other Published Studies

Number Of Injections Per Year (Median)	Our Results	Jacob et al^Citation10	Gillies et al^Citation9
Year 1	6	5	6
Year 2	4	3	5
Year 3	4	3	5
Year 4	4	3	6
Year 5	5	3	5
Year 6	4	2	5.5
Year 7	3	–	5
Year 8	3	–	–

Jacob J, Brie H, Leys A, et al. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. Int J Ophthalmol. 2017;10(1):81–90. doi:10.18240/ijo.2017.01.14

 Web of Science ®Google Scholar

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299.

 PubMed Web of Science ®Google Scholar

Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122(9):1837–1845. doi:10.1016/j.ophtha.2015.05.010

 PubMed Web of Science ®Google Scholar